|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 38/22 | (2006.01) |
| C07K 14/58 | (2013.01) | ||
| C07K 14/58 | (2006.01) | ||
| A61K 47/60 | (2017.08) | ||
| A61K 47/60 | (2017.01) | ||
| A61P 19/08 | (2018.01) | ||
| A61P 9/12 | (2018.01) | ||
| A61P 7/10 | (2006.01) | ||
| A61P 9/00 | (2006.01) | ||
| A61P 9/10 | (2018.01) | ||
| A61P 9/04 | (2006.01) | ||
| G01N2800/10 | (2013.01) | ||
| A61K 38/2242 | (2013.01) | ||
| A61P 9/10 | (2006.01) | ||
| A61P 9/12 | (2006.01) | ||
| G01N2333/58 | (2013.01) | ||
| A61P 13/12 | (2006.01) | ||
| A61P 7/10 | (2018.01) | ||
| A61P 19/00 | (2006.01) | ||
| G01N2800/52 | (2013.01) | ||
| A61P 19/08 | (2006.01) | ||
| A61K 38/00 | (2013.01) | ||
| A61P 21/00 | (2006.01) | ||
| G01N2800/105 | (2013.01) | ||
| A61P 19/00 | (2018.01) | ||
| A61P 13/12 | (2018.01) | ||
| A61P 9/00 | (2018.01) | ||
| A61P 21/00 | (2018.01) | ||
| A61K 38/22 | (2013.01) | ||
| A61P 9/04 | (2018.01) | ||
| G01N2800/385 | (2013.01) |
| (11) | Number of the document | 3175863 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16192229.9 |
| Date of filing the European patent application | 2010-05-20 | |
| (97) | Date of publication of the European application | 2017-06-07 |
| (45) | Date of publication and mention of the grant of the patent | 2021-12-01 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 180112 P | 2009-05-20 | US | |
| 254563 P | 2009-10-23 | US |
| (72) |
WENDT, Daniel, J. , US
AOYAGI-SCHARBER, Mika , US
LONG, Shinong , US
VELLARD, Michel, Claude , US
CASTILLO, Sianna , US
OKHAMAFE, Augustus, O. , US
PRICE, Christopher, P. , US
|
| (73) |
BioMarin Pharmaceutical Inc. ,
105 Digital Drive, Novato, CA 94949,
US
|
| (54) | VARIANTS OF C-TYPE NATRIURETIC PEPTIDE |
| VARIANTS OF C-TYPE NATRIURETIC PEPTIDE |